{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001598599","name":"Innate Pharma SA","summary":"Innate Pharma SA is a global, clinical-stage oncology-focused biotech company developing a portfolio of product candidates targeting immuno-oncology. Its pipeline includes monalizumab, lacutamab, IPH5201, IPH5301, IPH6401/SAR514, IPH6501, and IPH4502, focused on checkpoint inhibitors, tumor-targeting antibodies, and antibodies affecting the tumor microenvironment. The company co-develops assets with AstraZeneca and Sanofi, aiming to activate innate and adaptive immune systems against cancerous cells.","people":[],"products":[{"name":"monalizumab","type":"platform","description":"Checkpoint inhibitor co-developed with AstraZeneca, evaluated in Phase 1, 2, and 3 trials in combination with durvalumab and other therapies."},{"name":"lacutamab","type":"platform","description":"Clinical-stage antibody investigated in Phase 2 studies for CTCL and PTCL, including combination with GEMOX chemotherapy."},{"name":"IPH5201","type":"platform","description":"Clinical-stage antibody investigated in Phase 2 study in combination with durvalumab and chemotherapy, co-developed with AstraZeneca."},{"name":"IPH5301","type":"platform","description":"Clinical-stage antibody investigated in Phase 1 study in combination with paclitaxel and trastuzumab, sponsored by Institut Paoli-Calmettes."},{"name":"IPH6401/SAR514","type":"platform","description":"Co-developed with Sanofi; Phase 1/2 study in multiple myeloma being terminated early, refocused on autoimmune indications."},{"name":"IPH6501","type":"platform","description":"First-in-human Phase 1/2 study in B-Cell non-Hodgkin lymphoma."},{"name":"IPH4502","type":"platform","description":"First-in-human Phase 1 study in patients with advanced solid tumors expressing Nectin-4."},{"name":"Lumoxiti","type":"platform","description":"Previously commercialized product; commercial experience ended in December 2020."}],"partnerships":[{"partner_name":"AstraZeneca","partnership_type":"development","description":"Co-development agreement for monalizumab and IPH5201 covering advanced development, clinical studies, and potential future registration and marketing.","start_date":null},{"partner_name":"Sanofi","partnership_type":"development","description":"Partnership for research and development of IPH6401/SAR514, IPH62, and another program in solid tumors.","start_date":null},{"partner_name":"Institut Paoli-Calmettes","partnership_type":"development","description":"Sponsors Phase 1 clinical study of IPH5301 in combination with paclitaxel and trastuzumab.","start_date":null}],"affiliations":[],"origin":{"leaf":"b59c1eaaf27bd20b1a6f6729dd0305242db291144c69c1c0d5bd7acf4eacad12","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ba183ba696c43ee97847ed9a2064ff568e95fb80baea63def323d5b4db74a4c8","parent":"8cf7af3b9f86d9f020f8479d78c98cbbde80f53950022bb4d135e9eb2ea96a0c","source":"0001598599-26-000005","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":492,"hourly_limit":500,"remaining":8,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}